Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has announced new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). On August 31, 2024, the company's Compensation Committee granted restricted stock equity awards to four new non-executive employees, totaling up to 8,600 restricted shares of Abeona common stock. These awards are designed as a material inducement to employment.
The vesting schedule for these restricted stock awards is as follows: one-third of the shares will vest yearly on each anniversary of the Grant Date. Full vesting will occur on the third anniversary of the Grant Date, subject to each employee's continued employment with Abeona on the applicable vesting dates.
Abeona Therapeutics (Nasdaq: ABEO) ha annunciato nuovi incentivi per i dipendenti in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Il 31 agosto 2024, il Comitato di Compensazione dell'azienda ha concesso premi azionari vincolati a quattro nuovi dipendenti non esecutivi, per un totale di 8.600 azioni vincolate delle azioni ordinarie di Abeona. Questi premi sono progettati come un incentivo materiale all'impiego.
Il programma di maturazione per questi premi azionari vincolati è il seguente: un terzo delle azioni maturerà annualmente in ogni anniversario della data di concessione. La maturazione completa avverrà al terzo anniversario della data di concessione, a condizione che ciascun dipendente continui a essere assunto presso Abeona nelle date di maturazione applicabili.
Abeona Therapeutics (Nasdaq: ABEO) ha anunciado nuevas concesiones de incentivos para empleados de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4). El 31 de agosto de 2024, el Comité de Compensación de la empresa concedió premios de acciones restringidas a cuatro nuevos empleados no ejecutivos, por un total de 8,600 acciones restringidas de acciones ordinarias de Abeona. Estos premios están diseñados como un incentivo material para el empleo.
El cronograma de adquisición para estos premios de acciones restringidas es el siguiente: un tercio de las acciones se adquirirán anualmente en cada aniversario de la fecha de concesión. La adquisición completa ocurrirá en el tercer aniversario de la fecha de concesión, sujeto a que cada empleado continúe en su empleo con Abeona en las fechas de adquisición aplicables.
Abeona Therapeutics (Nasdaq: ABEO)는 Nasdaq 상장 규칙 5635(c)(4)에 따라 새로운 직원 유인 보상을 발표했습니다. 2024년 8월 31일, 회사의 보상 위원회는 네 명의 새로운 비임원 직원에게 총 8,600주의 제한된 주식을 부여했습니다. 이러한 보상은 고용에 대한 물질적인 유인책으로 설계되었습니다.
이 제한 주식 보상의 보유 일정은 다음과 같습니다: 주식의 1/3은 매년 부여일의 기념일에 만기됩니다. 전체 만기는 부여일의 세 번째 기념일에 발생하며, 이는 각 직원이 해당 만기일에 Abeona에 계속 고용되어 있어야 합니다.
Abeona Therapeutics (Nasdaq: ABEO) a annoncé de nouvelles incitations à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4). Le 31 août 2024, le Comité de Rémunération de l'entreprise a accordé des récompenses d'actions restreintes à quatre nouveaux employés non-exécutifs, pour un total de 8 600 actions restreintes des actions ordinaires d'Abeona. Ces récompenses sont conçues comme un incitatif matériel à l'emploi.
Le calendrier d'acquisition pour ces récompenses d'actions restreintes est le suivant : un tiers des actions sera acquis chaque année à chaque anniversaire de la date d'octroi. L'acquisition complète se produira à la troisième anniversaire de la date d'octroi, sous réserve que chaque employé soit toujours en emploi chez Abeona aux dates d'acquisition applicables.
Abeona Therapeutics (Nasdaq: ABEO) hat neue Mitarbeiteranreize gemäß Nasdaq-Listungsregel 5635(c)(4) angekündigt. Am 31. August 2024 gewährte das Vergütungskomitee des Unternehmens vier neuen nicht-executive Mitarbeitern eingeschränkte Aktienvergütungen in Höhe von insgesamt 8.600 eingeschränkten Aktien des Stammkapitals von Abeona. Diese Auszeichnungen sind als wesentlicher Anreiz für die Beschäftigung konzipiert.
Der Vesting-Plan für diese eingeschränkten Aktienverlängerungen ist wie folgt: ein Drittel der Aktien wird jährlich an jedem Jahrestag des Gewährungsdatums fällig. Die vollständige Vesting erfolgt am dritten Jahrestag des Gewährungsdatums, vorausgesetzt, jeder Mitarbeiter ist an den entsprechenden Vesting-Daten weiterhin bei Abeona beschäftigt.
- Attraction of new talent with equity incentives
- Alignment of employee interests with company performance through stock awards
- Potential dilution of existing shareholders' equity
CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On August 31, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,600 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous cell-based gene therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and results of ongoing testing and other corrective actions being performed in response to the FDA’s identified deficiencies, which could delay the Company’s BLA resubmission; the timing and outcome of the FDA’s review of our resubmission; the FDA’s grant of a Priority Review Voucher upon approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many new employees received equity awards from Abeona Therapeutics (ABEO)?
What is the total number of restricted shares granted by Abeona Therapeutics (ABEO) in this announcement?
What is the vesting schedule for the restricted stock awards granted by Abeona Therapeutics (ABEO)?
Under which Nasdaq rule did Abeona Therapeutics (ABEO) grant these equity awards?
